AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27059872 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 220
Study 27059872 — intervention group
Group type: COMPARATOR
Intervention: Subdural drain (SDD)
Number of subjects: 220
Study 27059973 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT arm
Number of subjects: 84
Study 27059973 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 84
Study 27060341 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg twice daily (maximum 200 mg twice daily) plus background antiretrovirals
Number of subjects: 0
Study 27061356 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ASD
Number of subjects: 84
Study 27061356 — intervention group
Group type: COMPARATOR
Intervention: Typical controls
Number of subjects: 84
Study 27061685 — intervention group
Group type: EXPERIMENTAL
Intervention: Postthrombotic limbs
Number of subjects: 22
Study 27061685 — intervention group
Group type: COMPARATOR
Intervention: Control limbs
Number of subjects: 22
Study 27061685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal foot vein in affected limbs
Number of subjects: 22
Study 27061685 — intervention group
Group type: COMPARATOR
Intervention: Dorsal foot vein in non-affected limbs
Number of subjects: 22
Study 27061685 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CFV pressure after walking
Number of subjects: 22
Study 27062495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic infrared thermography (IR)
Number of subjects: 25
Study 27063005 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0
Study 27063676 — intervention group
Group type: EXPERIMENTAL
Intervention: SPT-Random (SPT-R)
Number of subjects: 4
Study 27063676 — intervention group
Group type: EXPERIMENTAL
Intervention: SPT-Blocked (SPT-B)
Number of subjects: 4
Study 27063977 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX015 at 80 mg/day (14 days on, 7 days off)
Number of subjects: 41
Study 27063978 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX015 at 80 mg once a day (14 days on, 7 days off)
Number of subjects: 45
Study 27063978 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX015 at 120 mg once a day
Number of subjects: 45
Study 27063978 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX015 at 40 mg twice a day
Number of subjects: 45
Study 27063978 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX015 at 80 mg once a day
Number of subjects: 45
Study 27064032 — intervention group
Group type: EXPERIMENTAL
Intervention: TRI at 0 cm from the radius styloid process
Number of subjects: 606
Study 27064032 — intervention group
Group type: EXPERIMENTAL
Intervention: TRI at 1 cm from the radius styloid process
Number of subjects: 606
Study 27064032 — intervention group
Group type: EXPERIMENTAL
Intervention: TRI with arterial diameter to sheath diameter ratio ≤1
Number of subjects: 606
Study 27064032 — intervention group
Group type: COMPARATOR
Intervention: TRI at 2-5 cm from the radius styloid process
Number of subjects: 606
Study 27064675 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically sick participants (defined by the presence of two or more metabolic abnormalities)
Number of subjects: 1002
Study 27064675 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and normal weight patients who were metabolically healthy
Number of subjects: 1002
Study 27064675 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (compared to the composite group of normal weight and overweight patients)
Number of subjects: 1002
Study 27064675 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically abnormal phenotype
Number of subjects: 1002
Study 27064675 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of metabolic abnormality
Number of subjects: 1002
Study 27065848 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 1
Study 27065849 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 followed by carboplatin and etoposide
Number of subjects: 1
Study 27065913 — intervention group
Group type: EXPERIMENTAL
Intervention: Liking norm condition
Number of subjects: 0
Study 27065913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable variety condition
Number of subjects: 0
Study 27065913 — intervention group
Group type: COMPARATOR
Intervention: Health message condition
Number of subjects: 0
Study 27065913 — intervention group
Group type: COMPARATOR
Intervention: Descriptive norm condition
Number of subjects: 0
Study 27065913 — intervention group
Group type: COMPARATOR
Intervention: Neutral control condition
Number of subjects: 0
Study 27066336 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab self-administered biweekly over 6 weeks (n=149)
Number of subjects: 313
Study 27066336 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab self-administered monthly over 12 weeks (n=164)
Number of subjects: 313
Study 27066336 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab self-administration
Number of subjects: 313
Study 27066336 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab (both dosing schedules and devices)
Number of subjects: 313
Study 27066461 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antibiotic prophylaxis (CAP)
Number of subjects: 1987
Study 27066461 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 1987
Study 27066461 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive RCT
Number of subjects: 1987
Study 27066461 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hydroureteronephrosis
Number of subjects: 1987
Study 27066464 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone therapy (MPT)
Number of subjects: 35
Study 27066464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 35
Study 27066824 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of heart-healthy behaviors
Number of subjects: 54
Study 27066824 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalysts for behavior change
Number of subjects: 54
Study 27066824 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to adopting healthy habits
Number of subjects: 54
Study 27066824 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators for healthy behaviors
Number of subjects: 54
Study 27067081 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin treatment
Number of subjects: 30
Study 27067321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pod-intravaginal ring (pod-IVR) delivering a combination of TDF and MVC
Number of subjects: 0
Study 27067336 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (SXT) administered orally at a dose of 960 mg once daily
Number of subjects: 12
Study 27067896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation initiated in the emergency department (LOV-ED)
Number of subjects: 513
Study 27067896 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention control group
Number of subjects: 513
Study 27068030 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care sternal closure plus PRP
Number of subjects: 2000
Study 27068030 — intervention group
Group type: COMPARATOR
Intervention: Standard of care sternal closure
Number of subjects: 2000
Study 27068396 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-Mefloquine (ASMQ) fixed-dose combination
Number of subjects: 162
Study 27068662 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including preparation, process, and patient-centeredness
Number of subjects: 746
Study 27068662 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies including flexible protocol and stipends
Number of subjects: 746
Study 27070726 — intervention group
Group type: COMPARATOR
Intervention: Definite PCD (205 participants)
Number of subjects: 534
Study 27071063 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout homogenate (BSH) containing sulforaphane (SFN), dosage and duration not specified.
Number of subjects: 0
Study 27071063 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout homogenate (BSH) containing sulforaphane (SFN).
Number of subjects: 0
Study 27071399 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive care (mailed invitation followed by telephone outreach, offer of smoking cessation services, access to pharmacotherapy)
Number of subjects: 3006
Study 27071399 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive care
Number of subjects: 3006
Study 27071399 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3006
Study 27071497 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study 27071522 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus romidepsin (GEMRO regimen)
Number of subjects: 20
Study 27071922 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib 45 mg BID
Number of subjects: 21
Study 27071922 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib 30 mg BID
Number of subjects: 21
Study 27071922 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib (both doses)
Number of subjects: 21
Study 27072861 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle (nonsmoker, physically active ≥150 min/wk, BMI 18.5-25 kg/m², adherence to a modified Mediterranean diet)
Number of subjects: 64979
Study 27072861 — intervention group
Group type: EXPERIMENTAL
Intervention: All 4 healthy behaviors
Number of subjects: 64979
Study 27072954 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal latrepirdine (5 mg and 10 mg for EMs)
Number of subjects: 19
Study 27072954 — intervention group
Group type: COMPARATOR
Intervention: Oral latrepirdine (8.14 mg)
Number of subjects: 19
Study 27073910 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated MSCT-ST (A-MSCT)
Number of subjects: 125
Study 27073910 — intervention group
Group type: COMPARATOR
Intervention: Manual MSCT-ST (M-MSCT)
Number of subjects: 125
Study 27074035 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Primary Care Initiative practices
Number of subjects: 497
Study 27074725 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective abdominal surgery
Number of subjects: 604
Study 27074795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) abatacept (single dose at baseline) followed by 4 weeks break and then continuation of weekly SC abatacept from day 28.
Number of subjects: 49
Study 27075016 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous olaparib and irinotecan every 3 weeks (Part A)
Number of subjects: 25
Study 27075016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent olaparib and irinotecan every 2 weeks (Part B)
Number of subjects: 25
Study 27075016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent olaparib and irinotecan (Part B)
Number of subjects: 25
Study 27075016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both olaparib and irinotecan
Number of subjects: 25
Study 27075016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of olaparib and irinotecan
Number of subjects: 25
Study 27075906 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary vitamin B-12 intake during pregnancy
Number of subjects: 368
Study 27075906 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin B-12 concentrations
Number of subjects: 368
Study 27075906 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated MMA (>271 nmol/L)
Number of subjects: 368
Study 27075906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal genetic polymorphisms
Number of subjects: 368
Study 27076187 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) monitoring
Number of subjects: 138
Study 27076187 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 138
Study 27076187 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-region fragment of pro-adrenomedullin (MR-proADM)
Number of subjects: 138
Study 27076187 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature and white cell count
Number of subjects: 138
Study 27076187 — intervention group
Group type: COMPARATOR
Intervention: Non-infected controls (N = 70)
Number of subjects: 138
Study 27076275 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 single-nucleotide polymorphisms (SNPs) associated with childhood BMI gain
Number of subjects: 5906
Study 27076275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative allelic risk score (ARS) for childhood
Number of subjects: 5906
Study 27076275 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 single-nucleotide polymorphisms (SNPs) associated with adulthood BMI change
Number of subjects: 5906
Study 27076486 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM (Fitbit One)
Number of subjects: 95
Study 27076496 — intervention group
Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme (NFPP)
Number of subjects: 140
Study 27076496 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 140
Study 27076600 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone Antagonist (AA)
Number of subjects: 44
Study 27076600 — intervention group
Group type: COMPARATOR
Intervention: Renin-Guided Therapy (RGT)
Number of subjects: 44
Study 27076940 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 at 60 mg/m(2)/day
Number of subjects: 12
Study 27076940 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 at 70 mg/m(2)/day
Number of subjects: 12
Study 27076940 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 at 80 mg/m(2)/day
Number of subjects: 12
Study 27076940 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 with concurrent radiotherapy
Number of subjects: 12
Study 27077906 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation within one hour after skin closure and close neurological monitoring
Number of subjects: 492
Study 27077906 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation within one hour
Number of subjects: 492
Study 27077906 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients extubated within one hour
Number of subjects: 492
Study 27077906 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with delayed extubation
Number of subjects: 492
Study 27077906 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to extubate within one hour
Number of subjects: 492
Study 27078728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib, a small tyrosine kinase inhibitor
Number of subjects: 0
Study 27078728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, a therapeutic antibody
Number of subjects: 0
Study 27078728 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 0
Study 27078728 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgical resection
Number of subjects: 0
Study 27078728 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27079291 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual interviews using a semi-structured questionnaire
Number of subjects: 29
Study 27079291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural scripts related to body weight
Number of subjects: 29
Study 27079291 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of cultural scripts by health care providers
Number of subjects: 29
Study 27079334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy with aspirin and clopidogrel after PCI
Number of subjects: 4190
Study 27079334 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score models developed from baseline clinical variables
Number of subjects: 4190
Study 27080216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily
Number of subjects: 84
Study 27080216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 84
Study 27080574 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 374
Study 27080930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study 27080930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27080929 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant human IL-1 receptor antagonist) administered by daily subcutaneous injection for 2-6 weeks
Number of subjects: 30
Study 27081020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with native T1 mapping
Number of subjects: 129
Study 27081020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with T2 mapping
Number of subjects: 129
Study 27081020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with ECV calculation
Number of subjects: 129
Study 27081020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with Lake Louise criteria (LLC)
Number of subjects: 129
Study 27081020 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-T imaging with native T1 mapping
Number of subjects: 129
Study 27081020 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-T imaging with ECV calculation
Number of subjects: 129
Study 27081020 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-T imaging with Lake Louise criteria (LLC)
Number of subjects: 129
Study 27081020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with T2 mapping in chronic symptoms
Number of subjects: 129
Study 27081022 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 mapping in patients with HFpEF
Number of subjects: 36
Study 27081022 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV greater than the median in HFpEF cohort
Number of subjects: 36
Study 27081022 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV below the median in HFpEF cohort
Number of subjects: 36
Study 27081022 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analyses of ECV in HFpEF
Number of subjects: 36
Study 27082506 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective Cesarean Section (ECS)
Number of subjects: 2297
Study 27082506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonelective Cesarean Section (NECS)
Number of subjects: 2297
Study 27082506 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Delivery
Number of subjects: 2297
Study 27082506 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2297
Study 27082828 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 2
Study 27083333 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 97
Study 27083333 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan plus oxaliplatin (IROX)
Number of subjects: 97
Study 27083775 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline analysis through tumor-germline dyad sequencing
Number of subjects: 439
Study 27084275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic or likely pathogenic germline variants screening
Number of subjects: 71
Study 27084275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic germline BRCA2 variants screening
Number of subjects: 71
Study 27084277 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotoxic intensity modulated radiotherapy (IMRT)
Number of subjects: 35
Study 27084282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse educational oral feeding programme
Number of subjects: 120
Study 27084281 — intervention group
Group type: EXPERIMENTAL
Intervention: Antirheumatic treatment (biologicals and/or conventional synthetic DMARDs)
Number of subjects: 100
Study 27084281 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline US scores
Number of subjects: 100
Study 27084286 — intervention group
Group type: EXPERIMENTAL
Intervention: Free cataract surgery
Number of subjects: 833
Study 27084348 — intervention group
Group type: EXPERIMENTAL
Intervention: Etarfolatide (99m)Tc-EC20 imaging technique
Number of subjects: 25
Study 27084507 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine front-line
Number of subjects: 339
Study 27084534 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based treatment approach
Number of subjects: 367
Study 27084653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Proton Therapy (IMPT)
Number of subjects: 50
Study 27084692 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/d for 16 weeks, augmented with aripiprazole 2-10 mg/d if clinically warranted after 8 weeks
Number of subjects: 134
Study 27084692 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 10-20 mg/d
Number of subjects: 134
Study 27085172 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent oral polio vaccine (bOPV)
Number of subjects: 320
Study 27085172 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV
Number of subjects: 320
Study 27086090 — intervention group
Group type: EXPERIMENTAL
Intervention: trNS
Number of subjects: 20
Study 27086275 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation (3-6 months)
Number of subjects: 663
Study 27086275 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation (3-6 months) in men
Number of subjects: 663
Study 27086275 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation (3-6 months) in high risk women (2 or more HERDOO2 points)
Number of subjects: 663
Study 27086275 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation (3-6 months) in low risk women (1 or 0 HERDOO2 points)
Number of subjects: 663
Study 27087007 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg intravenous mepolizumab (MENSA)
Number of subjects: 711
Study 27087007 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg subcutaneous mepolizumab (SIRIUS)
Number of subjects: 711
Study 27087007 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab (both studies)
Number of subjects: 711
Study 27087007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study 27087478 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based HIV testing and streamlined ART
Number of subjects: 0
Study 27087478 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27087519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily plus pantoprazole 40 mg twice daily for 6 months
Number of subjects: 8
Study 27087519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin plus pantoprazole
Number of subjects: 8